22.09.2011 • News • Watson Pharmaceuticals

Watson Confirms Amphastar Patent Lawsuit

Generic drug maker Watson Pharmaceuticals Wednesday confirmed that Momenta Pharmaceuticals and Sandoz have filed suit against Amphastar Pharmaceuticals and Watson on September 21 in the US District Court for the District of Massachusetts. Watson and Amphastar intend to vigorously defend the claims in the lawsuit.

The suit alleges that Amphastar's Enoxaparin Sodium Injection product, which Watson has the exclusive right to distribute in the U.S. retail pharmacy channel, infringes Momenta's U.S. Patent Nos. 7,790,466 and 7,575,886. Enoxaparin Sodium Injection is a generic equivalent to Sanofi-Aventis' Lovenox.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Top-Feature